The potential role of mTOR inhibitors in non-small cell lung cancer.

The mammalian target of rapamycin (mTOR), a serine/threonine kinase, is a downstream mediator in the phosphatidylinositol 3-kinase/Akt signaling pathway, which plays a critical role in regulating basic cellular functions including cellular growth and proliferation. Currently, the mTOR inhibitor rapamycin and its analogues (CCI-779, RAD001, AP23573), which induce cell-cycle arrest in the G(1) phase, are being evaluated in cancer clinical trials. The mTOR inhibitors appear to be well tolerated, with skin reactions, stomatitis, myelosuppression, and metabolic abnormalities the most common toxicities seen. These adverse events are transient and reversible with interruption of dosing. Several pieces of evidence suggest a certain antitumor activity, including tumor regressions and prolonged stable disease, which has been reported among patients with a variety of malignancies, including non-small cell lung cancer (NSCLC). These promising preliminary clinical data have stimulated further research in this setting. Here, we review the basic structure of the pathway together with current results and future developments of mTOR inhibitors in the treatment of NSCLC patients.

[1]  M. Schreier,et al.  SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. , 1997, Transplantation.

[2]  George Thomas,et al.  Regulation of cell size in growth, development and human disease: PI3K, PKB and S6K , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[3]  Liang Qiao,et al.  Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. , 2002, Frontiers in bioscience : a journal and virtual library.

[4]  G. Tortora,et al.  Mechanisms of resistance to EGFR inhibitors , 2007, Targeted Oncology.

[5]  Shile Huang,et al.  Inhibition of Mammalian Target of Rapamycin Activates Apoptosis Signal-regulating Kinase 1 Signaling by Suppressing Protein Phosphatase 5 Activity* , 2004, Journal of Biological Chemistry.

[6]  E. Tuzcu,et al.  Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. , 2003, The New England journal of medicine.

[7]  J. Buckner,et al.  A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer , 2006, Clinical Cancer Research.

[8]  R. Abraham,et al.  Isolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian Cells (*) , 1995, The Journal of Biological Chemistry.

[9]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[10]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[11]  Tobias Schmelzle,et al.  TOR, a Central Controller of Cell Growth , 2000, Cell.

[12]  M. Kris,et al.  Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: A phase II trial , 2007 .

[13]  M. Kris,et al.  Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall‐cell lung cancer , 2007, Cancer.

[14]  T. Golub,et al.  The Immunosuppressant Rapamycin Mimics a Starvation-Like Signal Distinct from Amino Acid and Glucose Deprivation , 2002, Molecular and Cellular Biology.

[15]  M. Hidalgo,et al.  A randomized, phase II ECOG trial of two dose levels of temsirolimus (CCI-779) in patients with extensive stage small cell lung cancer in remission after induction chemotherapy. A preliminary report , 2005 .

[16]  A. Rosenwald,et al.  Deletions in the Long Arm of Chromosome 10 in Lymphomas With t(14;18): A Pathogenetic Role of the Tumor Suppressor Genes PTEN/MMAC1 and MXI1? , 1998 .

[17]  S. Mulgaonkar,et al.  Everolimus versus Mycophenolate Mofetil in the Prevention of Rejection in De Novo Renal Transplant Recipients: A 3-Year Randomized, Multicenter, Phase III Study , 2005, Transplantation.

[18]  E. Raymond,et al.  Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Price,et al.  Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. , 2005, Cancer research.

[20]  H. Lane,et al.  Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear Cells , 2004, Cancer Research.

[21]  J. Douros,et al.  New antitumor substances of natural origin. , 1981, Cancer treatment reviews.

[22]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[23]  F. Khuri,et al.  Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. , 2005, Cancer research.

[24]  R. Salgia,et al.  Receptor Tyrosine Kinases and Inhibitors in Lung Cancer , 2004, TheScientificWorldJournal.

[25]  J. Massagué,et al.  Rapamycin resistance tied to defective regulation of p27Kip1 , 1996, Molecular and cellular biology.

[26]  Tian Xu,et al.  Akt regulates growth by directly phosphorylating Tsc2 , 2002, Nature Cell Biology.

[27]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[28]  J. Avruch,et al.  Dissociation of raptor from mTOR is a mechanism of rapamycin‐induced inhibition of mTOR function , 2004, Genes to cells : devoted to molecular & cellular mechanisms.

[29]  T. Clackson,et al.  Anti-proliferative activity of the mTOR inhibitor AP23573 in combination with cytotoxic and targeted agents , 2004 .

[30]  L. Rozamus,et al.  Structure-based design of AP23573, a phosphorus-containing analog of rapamycin for anti-tumor therapy. , 2004 .

[31]  S. Sehgal.  Rapamune (Sirolimus, Rapamycin): An Overview and Mechanism of Action , 1995, Therapeutic drug monitoring.

[32]  M. Hidalgo,et al.  Current status of mammalian target of rapamycin inhibitors in lung cancer. , 2005, Clinical lung cancer.

[33]  C. Proud,et al.  Regulation of mammalian translation factors by nutrients. , 2002, European journal of biochemistry.

[34]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. , 1975, The Journal of antibiotics.

[35]  S. Schreiber,et al.  FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line. , 1993, The Journal of biological chemistry.

[36]  A. Rossi,et al.  A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics. , 2007, Clinical lung cancer.

[37]  Targeting mTOR signaling for lung cancer therapy. , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[38]  Li Mao,et al.  Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  V. Sexl,et al.  The Cyclin-dependent Kinase Inhibitor p21 cip1 Mediates the Growth Inhibitory Effect of Phorbol Esters in Human Venous Endothelial Cells* , 1997, The Journal of Biological Chemistry.

[40]  I. Judson,et al.  Results of a phase 1 clinical trial investigating a combination of the oral mTOR-inhibitor Everolimus (E, RAD001) and Gemcitabine (GEM) in patients (pts) with advanced cancers. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  John Mendelsohn,et al.  Epidermal growth factor receptor targeting in cancer. , 2006, Seminars in oncology.

[42]  Thomas J. Smith,et al.  American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  A. Arcaro,et al.  Targeting mTOR signaling in lung cancer. , 2007, Critical reviews in oncology/hematology.

[44]  R. Guo,et al.  Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. , 2006, Lung cancer.

[45]  J. Testa,et al.  Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. , 2004, Carcinogenesis.

[46]  N. Oshiro,et al.  Raptor, a binding partner of target of rapamycin. , 2004, Biochemical and biophysical research communications.

[47]  Christine C. Hudson,et al.  Regulation of Hypoxia-Inducible Factor 1α Expression and Function by the Mammalian Target of Rapamycin , 2002, Molecular and Cellular Biology.

[48]  E. Sausville,et al.  Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  T. Resink,et al.  Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR) ‐dependent signaling , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[50]  J. E. Sousa,et al.  Use of rapamycin-impregnated stents in coronary arteries. , 2003, Transplantation proceedings.

[51]  J. Jett,et al.  D7-07: A phase II NCCTG “Window of Opportunity Front-line” study of the mTOR Inhibitor, CCI-779 (Temsirolimus) given as a single agent in patients with advanced NSCLC , 2007 .

[52]  A. Tolcher,et al.  Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR Inhibitor, administered IV daily X 5 every other week in patients (pts) with refractory or advanced malignancies , 2004 .

[53]  G. Koehl,et al.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor , 2002, Nature Medicine.

[54]  C. Peschel,et al.  Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. , 2003, Blood.

[55]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[56]  D. Boffa,et al.  Rapamycin Inhibits the Growth and Metastatic Progression of Non-Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[57]  J. Blenis,et al.  Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression , 2004, Oncogene.

[58]  William Pao,et al.  Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus , 2007, Clinical Cancer Research.

[59]  M. Ratain,et al.  A phase I trial of a novel mTOR inhibitor AP23573 administered weekly (wkly) in patients (pts) with refractory or advanced malignancies: A pharmacokinetic (PK) and pharmacodynamic (PD) analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  K. Inoki,et al.  TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling , 2002, Nature Cell Biology.

[61]  C. Proud,et al.  Regulation of targets of mTOR (mammalian target of rapamycin) signalling by intracellular amino acid availability. , 2003, The Biochemical journal.

[62]  Kevin Carroll,et al.  Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.

[63]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[64]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[65]  L. Helman,et al.  The biology behind mTOR inhibition in sarcoma. , 2007, The Oncologist.